You are here: Industry Insights > vertex

News List

Vertex doubles size of cystic fibrosis drug discovery site fiercebiotech
June 25, 2018
Vertex has more than doubled the size of the San Diego research site that discovered its key cystic fibrosis drugs.
FDA halts CRISPR and Vertex’s upcoming gene editing trial biospectrumasia
June 04, 2018
The companies sought approval in April to begin the early-stage study in humans; it would be one of the first in the U.S. involving gene editing, a method of cutting out and replacing disease-causing snippets of DNA.
Vertex to test CF triple combo therapy in Phase III trials pharmatimes
April 28, 2018
Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
Vertex and NHS close in on cystic fibrosis drug pricing deal pharmaphorum
April 24, 2018
Vertex could be close to a price deal with the NHS over its portfolio of cystic fibrosis drugs, after health ministers wrote to the US firm asking for a conclusion to talks after almost two years of wrangling.
NHS drug deal could fund vital cystic fibrosis research pharmaphorum
March 06, 2018
Vertex’s research guru has warned that it could take another 15 years to produce a suite of medicines that treat all strains of the disease, saying that a deal with the NHS will be crucial to future development
Investors Elated as Vertex Picks Two Top CF Triple Combos for Phase III Trials biospace
February 02, 2018
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy.
Vertex’ CF therapy Orkambi cleared for younger patients pharmatimes
January 11, 2018
European regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation.
Vertex Ventures launches life sciences accelerator biospectrumasia
October 12, 2017
Vertex Ventures launches life sciences accelerator TLL is affiliated with the National University of Singapore (NUS) and Nanyang Technological University (NTU).
Sanofi, Shire, Vertex and more back first-ever rare disease film festival fiercepharma
August 31, 2017
Lucas DeFabio stars in one of the films set to be shown at the new rare-disease film festival, co-founded by his father, Daniel DeFabio, and Bo Bigelow.
FDA Approves KALYDECO (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who firstwordpharma
August 02, 2017
Vertex Pharmaceuticals Incorporated announced that the U.S. FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who...

Previous page 1 2 3 4 5 6 7 Next page